Scientists spy on every sip: GLP-1 drugs alter how we eat, not just what we eat
NCT ID NCT07457424
First seen Mar 18, 2026 · Last updated May 16, 2026 · Updated 9 times
Summary
This study looks at how GLP-1 receptor agonists (like Ozempic) change the way people eat, not just how much. Researchers will use a special device to measure every sip, suck, and pause while people drink high-sugar and high-fat liquids. The goal is to understand exactly how these drugs affect eating behavior, which could help explain weight loss outcomes. The study includes people with obesity taking GLP-1 drugs, those with obesity not taking them, and healthy-weight controls.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METABOLIC DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Research Centre
Dublin, Dublin, Dublin 4, Ireland
Conditions
Explore the condition pages connected to this study.